Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Grasping the Commencement of Criminal Cases: An Extensive Outline - 2Famous Versatile Brands: Your Decision
- 3‘RichTok’ Influencer Becca Bloom Shows Off Custom Invitations and ‘Most Valued Possession’ from Her Viral 2025 Wedding
- 4Spanish police and soldiers track boars, reinforce farm security amid swine fever outbreak
- 5The Minimized Passage Horse: Reconsidering a Symbol for the Cutting edge Period
- RFK Jr.'s vaccine panel delays hepatitis B shot vote after chaotic meeting
- AI is providing emotional support for employees – but is it a valuable tool or privacy threat?
- Iran plans new restrictions in overhaul of Strait of Hormuz rules
- Glamour Shots once ruled the mall. I went to one of the last ones standing.
- Smooth out Your Funds: Cash The board Simplified
- 6 Web-based Course Stages for Successful Learning and Educating
- South Korea launches Earth-observation satellite on homegrown Nuri rocket
- Explainer-What Novo Nordisk's weight-loss pill approval means for company, patients
- Manual for 6 famous sorts of cheddar
